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Abstract 
 
Background: The Bioavailabilty, efficacy and disease resistance of chemotherapy are the limitations of cancer 
treatment. This study was designed to formulate a microcapsules containing curcumin and retinylester as core material 
and tested the anti-cancer activity against different cancer cell lines.  
Materials and methods: This study involved the design and formulation of microcapsules containing curcumin and 
retinylester as (core materials) embedded in dextrin/gelatin as wall materials. It was examined by Fourier-transform 
infrared spectroscopy FTIR and tested against HeLa and HepG2 cancer cell lines.  
Results: Analysis of microcapsule by FTIR showed the characteristic band (2000cm
-1
~ 3800cm
-1
) that is indicated 
mainly from OH
-
, – CH3 and double bond. These bond stretching showed spectral bands peak 2975cm
-1
and 2670cm
-1
, 
2836cm
-1
 respectively. The anticancer activity of these microcapsules on HeLA and HepG2 showed inhibition percent 
87% and 85% respectively and non-toxic effect on normal cells.  
Conclusion: Micro capsulated form of curcumin-retinylester showed an efficient medicinal mixture displayed a 
significant effect to HeLa and HepG2 cells which is very promising effective in the treatment of cancer. 
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Introduction 
 
Curcuminoids are a functional foods related to  phenolic phytochemicals class usually produced  from the 
rhizomes of turmeric (Curcuma longa) spice (Chamras et al., 2002).  It was reported to have a number of beneficial 
biological activities as anti-inflammatory, antitumor, antimicrobial, gastric ulcers healing, irritable and pancreatic 
injury relive (Serini et al.,  2009).  Retinyl ester is the precursor of vitamin A that exert different biological activity 
such as vision in dark, stimulate immune response, maintenance of epithelial tissue and differentiation (Spencer et al., 
2009, Kimura et al., 2007 and Li et al., 2013).  However, curcumin and retinylester bioavailability is important is in 
drug delivery to target tissues to increase their efficacy and stability which will be used in pharmaceutical purposes. 
Micro capsulation is a new biotechnology to protect the nutrient from oxidation   and loss its biological activity 
(D’Eliseo et al., 2012) .This micro capsulation are resistance to enzymatic degradation and oxidation, and enhanced its 
bioavailability to target tissue (Kokura et al., 2012 and Sauer et al., 2007).  Many of the anticancer drugs that are 
widely clinically used today have high risks of adverse side effects and poor specificity and selectivity against tumors. 
Hence, an urgent need to encounter this problem by improving the efficacy, selectiveness and safety of the anti-tumor 
agents which can be done by modification with specific motifs by elevating the affinity for tumor cells and reach the 
biological targets (Siddiqui et al., 2011). The rational of this study was to produce microcapsules of curcumin and 
retinylester as core material and dextrin as wall material   characterization and evaluate the anti-proliferative and pro-
apoptotic effects on HeLa and HepG2. 
 
Materials and Methods 
Preparation of microcapsules 
 
The curcumin and retinylester were purchased from GNC company, Jeddah, Saudi Arabia, curcumin (purity 
99.6 %) and retinylester (purity 99.4 %). It was mixed in a ratio of 1:1.  
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The core material (curcumin /retinylester; 1:1 w/w), one ml of tween 80 as emulsifier was added and mixed well using 
sonicator for 10 min. Then, wall material (casein/gelatin, 4:1 ratio) was mixed at 39 
0
C for 16 hours. Particle size was 
measured by   size analyzer and characterized using  a PerkinElmer spectrum 100 FT-IR spectrometer. 
 
Assessment of Antitumor activity of microcapsules  
Cell culture and treatment 
 
 This study was carried out on cancer cell lines (HeLa and HepG2), it was obtained from  KAU. Cell lines was 
maintained in a humidified incubator with 5% CO2 at 37°C and grown in Dulbecco’s Modified Eagle’s Medium 
(DMEM)(UFC biotech, Riyadh, KSA) .The media were supplemented with 10% fetal bovine serum (FBS) (Gibco 
U.S.A) and 1% penicillin-streptomycin antibiotics (100 units/ml) (Gibco U.S.A). A 100 mM solution of studied 
compounds was prepared in 100% DMSO (Dimethyl sulfoxide, Gibco U.S.A) or water. From the stock solution, 
appropriate working concentrations were prepared in the culture media where the final concentration of DMSO was 
less than 0.1% in both untreated and treated cells. 
 
Cell viability assay 
 
The cell Proliferation assay test was based on the break of a tetrazolium salt (WST-1) by dehydrogenase in 
mitochondria to form formazan in viable cells. The higher the number of viable cells, the higher formazan produced 
following the addition of WST-1. It can be used also for detecting cytotoxicity. 
 Density of 10
4 
cells/well for HeLa, HepG2 and Baby Hamster Kidney fibroblasts BHK cells were maintained 
and seeded on 96-multiwell plates. The cells were grown till the exponential phase and exposed to different 
concentrations of prepared microencapsulated (10, 20 and 40 µM) for several time periods (24, 48 and 72 h). Cell 
proliferation rate was evaluated through a rapid colorimetric cell proliferation assay using WST-1 reagent (Sigma 
Aldrich, USA). After incubation for the above mentioned duration, 10 µL of WST-1 solution was added and incubated 
for an additional 1 h at 37
o
C. Finally, the absorbance was read at 450 nm with a ELx800™ micro plate ELISA reader 
(Biotek, USA) .Thymoquinone was used as a positive control. The percentage of cell viability was calculated by 
assuming control (untreated) samples as 100 % viable (Cockbain et al., 2012). The IC50 (50% inhibitory concentration) 
values were calculated from the dose-response curves. 
 
Apoptosis assay 
   
 Apoptosis was a good indicator of cancer recovery. HeLa and HepG2 cells were poured in a 96-well plate at a 
density of 10
4
 cells /well and incubated for 24 h. After treating the cells with different doses of microcapsules for 
several time periods, Annexin V/7AAD was determined according to manufacturer’s protocol. Briefly, 100 µl of 
Annexin reagent staining solution (containing annexin V fluorescein and 7AAD) was added and incubated at room 
temperature for 20 min in dark. The forward and side scatter was recorded at 10,000 events and the subsequent 
percentage of the early and the late apoptotic cells was analyzed using the Guava Benchtop Flow Cytometer and the 
results plotted using the In Cyte™ software (Millipore®, Billerica, MA). 
 
Statistical analysis 
 
 Results were expressed as mean + SE. Student’s t test was carried out for statistical analysis for the group 
comparison between the pairs. One way analysis of variance (ANOVA) was performed using SPSS version 15 
 
Results and Discussion 
FTIR analysis of microencapsulated  
 
Results in Fig. 1 described FTIR analysis of prepared microcapsule. It showed the characteristic band 
(2000cm
-1
 ~ 3800cm
-1) is mainly seen from “OH”, –CH3 and double bonds. These bonds stretching showed spectral 
bands peak 2975cm-
1
and 2670cm-
1
, 2836cm-
1
 respectively. The wall materials mainly contain these bonds and so the 
characteristic peaks were found in the wall materials as well as in microcapsule. Curcumin contains two - OH and two 
–CH3 groups at side chain while retinyleaster contain four double bonds, displayed strong absorption peak at 2836cm
-1
. 
This spectral absorption is attributed to OH
-
 bond stretching vibration but –CH3 bond absorption was strongest in the 
microcapsule that is caused by the core material. In addition spectral bands, 2836cm
-1
 was found that correspond to the 
retinyl group due to four double bonds. Epidemiological studies reported that, a vitamin A is inversely related to cancer 
development. Vitamin A showed a decrease the incidence of chemically induced tumor in animals [Wen et al., 2003]. 
In addition, vitamin A inhibited the development of some types of tumors, including breast, lung and prostatic cancers 
(Harris et al., 2013). 
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Figure 1: FTIR analysis of microencapsulated for of curcumin and retinylester. 
 
Table 1. IC50 values (µM) of the microcapsules against tumor cells and the normal cells are presented as + S.E.M.  
 
 
 
 
 
 
 
 
 
 
 
Experiment was done triplicate (a): p < 0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
        Figure 2. Antiproliferation activity of different concentrations of Microcapsules. 
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Anti-proliferation activity of Microcapsules 
 
          To determine the selectivity of microcapsules, at a concentration of 10 µM, significantly caused cell proliferation 
inhibition of HeLa cells by about 91%  (p<0.001). However, increasing the concentration to 20 µM induced a cell 
proliferation inhibition in HeLa and Hep2G by about 85% and 87% (p<0.001) respectively The cell viability at the 
highest concentration of 40 µM were found to be 23.3 %, 33 %, respectively for a time incubation of 24 h respectively 
(fig 2). 
These results showed the combined effects of curcumin and retinylester on treating HeLa. Previous study 
found that inhibitory effect of retinylester on HepG2  and HeLa can be enhanced with the addition of curcumin. The 
mechanism has two aspects. Firstly, curcumin may reduce the oxidation reaction. Secondly, curcumin, itself has 
obvious effect of inhibiting tumor. Haast et al. (2014) demonstrated that curcumin can make tumor cells sensitive, 
especially human colon carcinoma cells. When different concentration of these microcapsules were used, the inhibitory 
rate was decreased by 20.587%, 22.6% respectively. The synergistic anticancer effects fall decreased slowly with 
decreasing concentration of mirocapsulation (Williams  et al., 2011 and Pot et al., 2008). However, the inhibition rate 
of the mixture wills no longer increase that may be associated with low substrate concentration (Brown et al., 2010 and 
Thiebaut et al., 2009). Hence, for the longer antitumor activity of the capsule it is advised to increase the concentration 
of retinylester in the treatment therapy. 
 
Detection of apoptosis 
 
 Finally, to confirm the intimacy of compounds 1, 7 and 8 , apoptosis mechanism in HeLa and HepG2 was 
investigated. Annexin V-7AAD staining of the  HeLa cells which were treated with increasing concentrations 10,20,14 
uM for 24 h was detected. Increasing the concentrations was associated with an increase in the number of apoptotic 
cells. It was found that, began to significantly trigger apoptosis at 10 µM. While at a concentration of 40 µM, the 
percentage of the annexin V positive cells was higher and approximately consistent with the value detected in cell 
viability assays  
 
Conclusion 
 
The prepared microencapsulation of curcumin-retinylester enhance the bioavailability and showed synergistic 
effect on HeLa and Hep2 G cells with significantly higher anti-cancer activity. These combination of curcumin-
retinylester considered as promising chemotherapy  in treatment of some cancer types. 
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